SCHEMBL5769923

SCHEMBL5769923

Brc1cccc(-n2cncn2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALOX5 P09917 2/20 0.36
LMNA P02545 1/20 0.35
PIM1 P11309 1/20 0.35
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28303005 0.86 CYP2A6 (0.47) CYP2A6ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL17781700 0.74 ALDH1A1 (0.40) CYP2A6ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL16419707 0.74 IRAK4 (0.38) CYP2A6ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL18168008 0.73 KDM4E (0.50) ALDH1A1MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL30261053 0.72 KDM4E (0.50) ALDH1A1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL4289 0.72 KDM4E (0.50) ALDH1A1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL8924809 0.72 IRAK4 (0.39) CYP2A6ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL3372137 0.71 GRIN1 (0.39) CYP2A6ALDH1A1MAPTGRIN1GRIN2B
SCHEMBL7209327 0.71 ALDH1A1 (0.36) CYP2A6ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL4897073 0.70 GRIN2D (0.38) ALDH1A1MAPTGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383768-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2006-09-06 EP disclosed
US-7030128-B2 Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction MERCK SHARP & DOHME LTD. (GB) 2006-04-18 US disclosed
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA4 CYP2A6 425/4885ALDH1A1 495/4885MAPT 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.